HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Appointments In Brief

This article was originally published in The Rose Sheet

Executive Summary

Avon taps Cramb: Former Gillette exec Charles Cramb is appointed to newly created position of Avon exec VP, finance and technology and CFO, assuming responsibilities of Exec VP and CFO Robert Corti, who is retiring after 30 years with the company, direct-seller announces. Effective Nov. 1, Cramb will report to CEO Andrea Jung. New role was created in line with firm's plan to integrate finance, business transformation and technology under one umbrella, Avon notes. Cramb previously served as Gillette senior VP finance and CFO, a role in which he helped orchestrate the company's successful restructuring program, Avon said. Firm notes his experience will be an "important asset" as it enters its next phase of transformation. Corti will remain with the firm through Q1 in a non-finance related capacity...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel